SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-17-009201
Filing Date
2017-02-24
Accepted
2017-02-24 17:06:58
Documents
6
Period of Report
2017-02-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 ONCOCYTE CORPORATION 8-K 2-17-2017 form8k.htm 8-K 31019
2 EXHIBIT 4.1 ex4_1.htm EX-4.1 97034
3 EXHIBIT 10.1 ex10_1.htm EX-10.1 40484
4 EXHIBIT 10.2 ex10_2.htm EX-10.2 40107
5 EXHIBIT 99.1 ex99_1.htm EX-99.1 12489
6 logo1.jpg GRAPHIC 6032
  Complete submission text file 0001140361-17-009201.txt   230953
Mailing Address 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501
Business Address 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA 94501 510-775-0515
OncoCyte Corp (Filer) CIK: 0001642380 (see all company filings)

IRS No.: 271041563 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37648 | Film No.: 17638333
SIC: 2835 In Vitro & In Vivo Diagnostic Substances